April 2014 | The Journal of Targeted Therapies in Cancer

May 22, 2014

In an interview with Targeted Therapies, Wierda discussed new treatments for CLL, including issues in translating these regimens into clinical practice.

May 12, 2014

Amid advances in targeted therapies for patients with chronic lymphocytic leukemia (CLL), researchers also have been making strides in the realm of chemoimmunotherapy regimens for the disease.

May 08, 2014

Despite initial clinical benefit of erlotinib and geftinib, overall efficacy of these agents is limited by emergence of drug-resistance mutations, including the gatekeeper T790M mutation.

May 06, 2014

Advanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.

May 01, 2014

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the treatment of CRPC.

April 29, 2014

Targeted Oncology spoke about progress in the treatment of HER2-positive breast cancer with breast cancer expert, Sunil Verma, MD, MSEd, FRCPC.

April 24, 2014

Increasing efficacy with cancer vaccines, oncolytic viruses, and checkpoint inhibitors in clinical trials led to immunotherapy, as a whole, being deemed Breakthrough of the Year by Science magazine in 2013.

April 23, 2014

The RAS-RAF-MEK-extracellular signal–regulated kinase 1 and 2 (ERK1/2) pathway is the most mutated pathway in human cancer. Thus, components of this pathway have been seen as promising targets for cancer therapy.